[1]
Kakhlon, O.; Cabantchik, Z.I. The labile iron pool: Characterization, measurement, and participation in cellular processes. Free Radic. Biol. Med., 2002, 33(8), 1037-1046.
[2]
Crichton, R.; Boelaert, J.R.; Braun, V.; Hantke, K.; Marx, J.J.M.; Santos, M.; Ward, R. Inorg. Biochem. Iron Metab; John Wiley & Sons, 2001.
[3]
Halliwell, B. Biochemistry of oxidative stress. Biochem. Soc. Trans., 2007, 35(Pt 5), 1147-1150.
[4]
Jomova, K.; Valko, M. Advances in metal-induced oxidative stress and human disease. Toxicology, 2011, 283(2-3), 65-87.
[5]
Horwitz, L.D.; Rosenthal, E.A. Iron-mediated cardiovascular injury. Vasc. Med., 1999, 4(2), 93-99.
[6]
Trinder, D.; Fox, C.; Vautier, G.; Olynyk, J.K. Molecular pathogenesis of iron overload. Gut, 2002, 51(2), 290-295.
[7]
Kremastinos, D.T.; Farmakis, D. Iron overload cardiomyopathy in clinical practice. Circulation, 2011, 124(20), 2253-2263.
[8]
Weidemann, F.; Rummey, C.; Bijnens, B.; Stork, S.; Jasaityte, R.; Dhooge, J.; Baltabaeva, A.; Sutherland, G.; Schulz, J.B.; Meier, T. Mitochondrial Protection With Idebenone In Cardiac Or Neurological Outcome Study, G. The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation, 2012, 125(13), 1626-1634.
[9]
Perrelli, M.G.; Pagliaro, P.; Penna, C. Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species. World J. Cardiol., 2011, 3(6), 186-200.
[10]
Horwitz, L.D.; Leff, J.A. Catalase and hydrogen peroxide cytotoxicity in cultured cardiac myocytes. J. Mol. Cell. Cardiol., 1995, 27(3), 909-915.
[11]
Reif, D.W. Ferritin as a source of iron for oxidative damage. Free Radic. Biol. Med., 1992, 12(5), 417-427.
[12]
Mladenka, P.; Simunek, T.; Hubl, M.; Hrdina, R. The role of reactive oxygen and nitrogen species in cellular iron metabolism. Free Radic. Res., 2006, 40(3), 263-272.
[13]
Kiechl, S.; Willeit, J.; Egger, G.; Poewe, W.; Oberhollenzer, F. Body iron stores and the risk of carotid atherosclerosis: Prospective results from the Bruneck study. Circulation, 1997, 96(10), 3300-3307.
[14]
Kraml, P. The role of iron in the pathogenesis of atherosclerosis. Physiol. Res., 2017, 66(Suppl. 1), S55-S67.
[15]
Simunek, T.; Sterba, M.; Popelova, O.; Adamcova, M.; Hrdina, R.; Gersl, V. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep., 2009, 61(1), 154-171.
[16]
Hrdina, R.; Gersl, V.; Klimtova, I.; Simunek, T.; Machackova, J.; Adamcova, M. Anthracycline-induced cardiotoxicity. Acta Med. (Hradec Kralove), 2000, 43(3), 75-82.
[17]
Hershko, C.; Link, G.; Tzahor, M.; Kaltwasser, J.P.; Athias, P.; Grynberg, A.; Pinson, A. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: Studies in rat heart cells in culture. J. Lab. Clin. Med., 1993, 122(3), 245-251.
[18]
Lipshultz, S.E.; Lipsitz, S.R.; Kutok, J.L.; Miller, T.L.; Colan, S.D.; Neuberg, D.S.; Stevenson, K.E.; Fleming, M.D.; Sallan, S.E.; Franco, V.I.; Henkel, J.M.; Asselin, B.L.; Athale, U.H.; Clavell, L.A.; Michon, B.; Laverdiere, C.; Larsen, E.; Kelly, K.M.; Silverman, L.B. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer, 2013, 119(19), 3555-3562.
[19]
Mann, D.L.; Kent, R.L.; Parsons, B.; Cooper, G. m 4th. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation, 1992, 85(2), 790-804.
[20]
Dhalla, N.S.; Adameova, A.; Kaur, M. Role of catecholamine oxidation in sudden cardiac death. Fundam. Clin. Pharmacol., 2010, 24(5), 539-546.
[21]
Osteraas, N.D.; Lee, V.H. Neurocardiology. Handb. Clin. Neurol., 2017, 140, 49-65.
[22]
Costa, V.M.; Carvalho, F.; Bastos, M.L.; Carvalho, R.A.; Carvalho, M.; Remiao, F. Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases. Curr. Med. Chem., 2011, 18(15), 2272-2314.
[23]
Hašková, P.; Kovaříková, P.; Koubková, L.; Vávrová, A.; Macková, E.; Simůnek, T. Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity. Free Radic. Biol. Med., 2011, 50(4), 537-549.
[24]
Cohen, A.R.; Galanello, R.; Pennell, D.J.; Cunningham, M.J.; Vichinsky, E. Thalassemia. Hematol-Am. Soc. Hematol.
Educ. Program., 2004. 14-34.
[25]
Galey, J.B. Recent advances in the design of iron chelators against oxidative damage. Mini Rev. Med. Chem., 2001, 1(3), 233-242.
[26]
Borgna-Pignatti, C.; Cappellini, M.D.; De Stefano, P.; Del Vecchio, G.C.; Forni, G.L.; Gamberini, M.R.; Ghilardi, R.; Origa, R.; Piga, A.; Romeo, M.A.; Zhao, H.; Cnaan, A. Survival and complications in thalassemia. Ann. N. Y. Acad. Sci., 2005, 1054, 40-47.
[27]
Buss, J.L.; Torti, F.M.; Torti, S.V. The role of iron chelation in cancer therapy. Curr. Med. Chem., 2003, 10(12), 1021-1034.
[28]
Saletta, F.; Suryo Rahmanto, Y.; Noulsri, E.; Richardson, D.R. Iron chelator-mediated alterations in gene expression: Identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53. Mol. Pharmacol., 2010, 77(3), 443-458.
[29]
van Asbeck, B.S.; Georgiou, N.A.; van der Bruggen, T.; Oudshoorn, M.; Nottet, H.S.; Marx, J.J. Anti-HIV effect of iron chelators: Different mechanisms involved. J. Clin. Virol., 2001, 20(3), 141-147.
[30]
Reelfs, O.; Eggleston, I.M.; Pourzand, C. Skin protection against UVA-induced iron damage by multiantioxidants and iron chelating drugs/prodrugs. Curr. Drug Metab., 2010, 11(3), 242-249.
[31]
Duffy, S.J.; Biegelsen, E.S.; Holbrook, M.; Russell, J.D.; Gokce, N.; Keaney, J.F., Jr; Vita, J.A. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation, 2001, 103(23), 2799-2804.
[32]
Kwiatkowski, A.; Ryckewaert, G.; Jissendi Tchofo, P.; Moreau, C.; Vuillaume, I.; Chinnery, P.F.; Destee, A.; Defebvre, L.; Devos, D. Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. Parkinsonism Relat. Disord., 2012, 18(1), 110-112.
[33]
Salkovic-Petrisic, M.; Knezovic, A.; Osmanovic-Barilar, J.; Smailovic, U.; Trkulja, V.; Riederer, P.; Amit, T.; Mandel, S.; Youdim, M.B. Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer’s disease. Life Sci., 2015, 136, 108-119.
[34]
Ward, R.J.; Dexter, D.T.; Crichton, R.R. Neurodegenerative diseases and therapeutic strategies using iron chelators. J. Trace Elem. Med. Biol., 2015, 31, 267-273.
[35]
Chan, W.; Taylor, A.J.; Ellims, A.H.; Lefkovits, L.; Wong, C.; Kingwell, B.A.; Natoli, A.; Croft, K.D.; Mori, T.; Kaye, D.M.; Dart, A.M.; Duffy, S.J. Effect of iron chelation on myocardial infarct size and oxidative stress in ST-elevation-myocardial infarction. Circ. Cardiovasc. Interv., 2012, 5(2), 270-278.
[36]
Neckar, J.; Boudikova, A.; Mandikova, P.; Sterba, M.; Popelova, O.; Miksik, I.; Dabrowska, L.; Mraz, J.; Gersl, V.; Kolar, F. Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts. Can. J. Physiol. Pharmacol., 2012, 90(9), 1303-1310.
[37]
Kwiatkowski, J.L. Real-world use of iron chelators. Hematology (Am. Soc. Hematol. Educ. Program), 2011, 2011, 451-458.
[38]
Pennell, D.J.; Berdoukas, V.; Karagiorga, M.; Ladis, V.; Piga, A.; Aessopos, A.; Gotsis, E.D.; Tanner, M.A.; Smith, G.C.; Westwood, M.A.; Wonke, B.; Galanello, R. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood, 2006, 107(9), 3738-3744.
[39]
Galanello, R.; Kattamis, A.; Piga, A.; Fischer, R.; Leoni, G.; Ladis, V.; Voi, V.; Lund, U.; Tricta, F. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica, 2006, 91(9), 1241-1243.
[40]
Modell, B.; Khan, M.; Darlison, M. Survival in beta-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet, 2000, 355(9220), 2051-2052.
[41]
Maggio, A.; Filosa, A.; Vitrano, A.; Aloj, G.; Kattamis, A.; Ceci, A.; Fucharoen, S.; Cianciulli, P.; Grady, R.W.; Prossomariti, L.; Porter, J.B.; Iacono, A.; Cappellini, M.D.; Bonifazi, F.; Cassara, F.; Harmatz, P.; Wood, J.; Gluud, C. Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol. Dis., 2011, 47(3), 166-175.
[42]
Farber, N.E.; Vercellotti, G.M.; Jacob, H.S.; Pieper, G.M.; Gross, G.J. Evidence for a role of iron-catalyzed oxidants in functional and metabolic stunning in the canine heart. Circ. Res., 1988, 63(2), 351-360.
[43]
Phaelante, A.; Rohde, L.E.; Lopes, A.; Olsen, V.; Tobar, S.A.; Cohen, C.; Martinelli, N.; Biolo, A.; Dal-Pizzol, F.; Clausell, N.; Andrades, M. N-acetylcysteine plus deferoxamine improves cardiac function in wistar rats after non-reperfused acute myocardial infarction. J. Cardiovasc. Transl. Res., 2015, 8(5), 328-337.
[44]
Ryter, S.W.; Si, M.; Lai, C.C.; Su, C.Y. Regulation of endothelial heme oxygenase activity during hypoxia is dependent on chelatable iron. Am. J. Physiol. Heart Circ. Physiol., 2000, 279(6), H2889-H2897.
[45]
Reddy, B.R.; Wynne, J.; Kloner, R.A.; Przyklenk, K. Pretreatment with the iron chelator desferrioxamine fails to provide sustained protection against myocardial ischaemia-reperfusion injury. Cardiovasc. Res., 1991, 25(9), 711-718.
[46]
Bendova, P.; Mackova, E.; Haskova, P.; Vavrova, A.; Jirkovsky, E.; Sterba, M.; Popelova, O.; Kalinowski, D.S.; Kovarikova, P.; Vavrova, K.; Richardson, D.R.; Simunek, T. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem. Res. Toxicol., 2010, 23(6), 1105-1114.
[47]
Haskova, P.; Koubkova, L.; Vavrova, A.; Mackova, E.; Hruskova, K.; Kovarikova, P.; Vavrova, K.; Simunek, T. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity. Toxicology, 2011, 289(2-3), 122-131.
[48]
El-Demerdash, E.; Mohamadin, A.M. Does oxidative stress contribute in tricyclic antidepressants-induced cardiotoxicity? Toxicol. Lett., 2004, 152(2), 159-166.
[49]
Dobsak, P.; Siegelova, J.; Wolf, J.E.; Rochette, L.; Eicher, J.C.; Vasku, J.; Kuchtickova, S.; Horky, M. Prevention of apoptosis by deferoxamine during 4 hours of cold cardioplegia and reperfusion: In vitro study of isolated working rat heart model. Pathophysiology, 2002, 9(1), 27.
[50]
Saad, S.Y.; Najjar, T.A.; Al-Rikabi, A.C. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol. Res., 2001, 43(3), 211-218.
[51]
Voest, E.E.; van Acker, S.A.; van der Vijgh, W.J.; van Asbeck, B.S.; Bast, A. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. J. Mol. Cell. Cardiol., 1994, 26(9), 1179-1185.
[52]
Herman, E.H.; Zhang, J.; Ferrans, V.J. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother. Pharmacol., 1994, 35(2), 93-100.
[53]
Hassan, M.A.; Tolba, O.A. Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: A comparative study of deferasirox and deferoxamine. Electron. Physician, 2016, 8(5), 2425-2431.
[54]
Ryals, B.; Westbrook, E.; Schacht, J. Morphological evidence of ototoxicity of the iron chelator deferoxamine. Hear. Res., 1997, 112(1-2), 44-48.
[55]
Beresewicz, A.; Horackova, M. Alterations in electrical and contractile behavior of isolated cardiomyocytes by hydrogen peroxide: Possible ionic mechanisms. J. Mol. Cell. Cardiol., 1991, 23(8), 899-918.
[56]
Hoffbrand, A.V.; Cohen, A.; Hershko, C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood, 2003, 102(1), 17-24.
[57]
Anderson, L.J.; Wonke, B.; Prescott, E.; Holden, S.; Walker, J.M.; Pennell, D.J. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet, 2002, 360(9332), 516-520.
[58]
Piga, A.; Gaglioti, C.; Fogliacco, E.; Tricta, F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica, 2003, 88(5), 489-496.
[59]
Borgna-Pignatti, C.; Cappellini, M.D.; De Stefano, P.; Del Vecchio, G.C.; Forni, G.L.; Gamberini, M.R.; Ghilardi, R.; Piga, A.; Romeo, M.A.; Zhao, H.; Cnaan, A. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood, 2006, 107(9), 3733-3737.
[60]
Tanner, M.A.; Galanello, R.; Dessi, C.; Smith, G.C.; Westwood, M.A.; Agus, A.; Roughton, M.; Assomull, R.; Nair, S.V.; Walker, J.M.; Pennell, D.J. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation, 2007, 115(14), 1876-1884.
[61]
van der Kraaij, A.M.; van Eijk, H.G.; Koster, J.F. Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. Circulation, 1989, 80(1), 158-164.
[62]
Barnabe, N.; Zastre, J.A.; Venkataram, S.; Hasinoff, B.B. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic. Biol. Med., 2002, 33(2), 266-275.
[63]
Link, G.; Tirosh, R.; Pinson, A.; Hershko, C. Role of iron in the potentiation of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J. Lab. Clin. Med., 1996, 127(3), 272-278.
[64]
Xu, L.J.; Jin, L.; Pan, H.; Zhang, A.Z.; Wei, G.; Li, P.P.; Lu, W.Y. Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. Acta Pharmacol. Sin., 2006, 27(10), 1333-1339.
[65]
Popelova, O.; Sterba, M.; Simunek, T.; Mazurova, Y.; Guncova, I.; Hroch, M.; Adamcova, M.; Gersl, V. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. J. Pharmacol. Exp. Ther., 2008, 326(1), 259-269.
[66]
Cohen, A.R.; Galanello, R.; Piga, A.; De Sanctis, V.; Tricta, F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood, 2003, 102(5), 1583-1587.
[67]
Waldmeier, P.C.; Buchle, A.M.; Steulet, A.F. Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo. Biochem. Pharmacol., 1993, 45(12), 2417-2424.
[68]
Hershko, C.; Konijn, A.M.; Nick, H.P.; Breuer, W.; Cabantchik, Z.I.; Link, G. ICL670A: a new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood, 2001, 97(4), 1115-1122.
[69]
Wood, J.C.; Kang, B.P.; Thompson, A.; Giardina, P.; Harmatz, P.; Glynos, T.; Paley, C.; Coates, T.D. The effect of deferasirox on cardiac iron in thalassemia major: Impact of total body iron stores. Blood, 2010, 116(4), 537-543.
[70]
Taher, A.; Cappellini, M.D. Update on the use of deferasirox in the management of iron overload. Ther. Clin. Risk Manag., 2009, 5, 857-868.
[71]
Pennell, D.J.; Porter, J.B.; Cappellini, M.D.; El-Beshlawy, A.; Chan, L.L.; Aydinok, Y.; Elalfy, M.S.; Sutcharitchan, P.; Li, C.K.; Ibrahim, H.; Viprakasit, V.; Kattamis, A.; Smith, G.; Habr, D.; Domokos, G.; Roubert, B.; Taher, A. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood, 2010, 115(12), 2364-2371.
[72]
Glickstein, H.; El, R.B.; Link, G.; Breuer, W.; Konijn, A.M.; Hershko, C.; Nick, H.; Cabantchik, Z.I. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Blood, 2006, 108(9), 3195-3203.
[73]
Al-Rousan, R.M.; Paturi, S.; Laurino, J.P.; Kakarla, S.K.; Gutta, A.K.; Walker, E.M.; Blough, E.R. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil. Am. J. Hematol., 2009, 84(9), 565-570.
[74]
Lal, A.; Porter, J.; Sweeters, N.; Ng, V.; Evans, P.; Neumayr, L.; Kurio, G.; Harmatz, P.; Vichinsky, E. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol. Dis., 2013, 50(2), 99-104.
[75]
Aydinok, Y.; Kattamis, A.; Cappellini, M.D.; El-Beshlawy, A.; Origa, R.; Elalfy, M.; Kilinc, Y.; Perrotta, S.; Karakas, Z.; Viprakasit, V.; Habr, D.; Constantinovici, N.; Shen, J.; Porter, J.B. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood, 2015, 125(25), 3868-3877.
[76]
Jansová, H.; Macháček, M.; Wang, Q.; Hašková, P.; Jirkovská, A.; Potůčková, E.; Kielar, F.; Franz, K.J.; Simůnek, T. Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury. Free Radic. Biol. Med., 2014, 74, 210-221.
[77]
Hasinoff, B.B.; Patel, D.; Wu, X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic. Biol. Med., 2003, 35(11), 1469-1479.
[78]
Hoffbrand, A.V.; Taher, A.; Cappellini, M.D. How I treat transfusional iron overload. Blood, 2012, 120(18), 3657-3669.
[80]
CDC Deaths associated with hypocalcemia from chelation therapy--Texas, Pennsylvania, and Oregon, 2003-2005. MMWR Morb. Mortal. Wkly. Rep., 2006, 55(8), 204-207.
[81]
Ibad, A.; Khalid, R.; Thompson, P.D. Chelation therapy in the treatment of cardiovascular diseases. J. Clin. Lipidol., 2016, 10(1), 58-62.
[82]
Lamas, G.A.; Ackermann, A. Clinical evaluation of chelation therapy: is there any wheat amidst the chaff? Am. Heart J., 2000, 140(1), 4-5.
[83]
Green, D.J.; O’Driscoll, J.G.; Maiorana, A.; Scrimgeour, N.B.; Weerasooriya, R.; Taylor, R.R. Effects of chelation with EDTA and vitamin B therapy on nitric oxide-related endothelial vasodilator function. Clin. Exp. Pharmacol. Physiol., 1999, 26(11), 853-856.
[84]
Knudtson, M.L.; Wyse, D.G.; Galbraith, P.D.; Brant, R.; Hildebrand, K.; Paterson, D.; Richardson, D.; Burkart, C.; Burgess, E. PATCH Investigators. Chelation therapy for ischemic heart disease: A randomized controlled trial. JAMA, 2002, 287(4), 481-486.
[85]
Ernst, E. Chelation therapy for coronary heart disease: An overview of all clinical investigations. Am. Heart J., 2000, 140(1), 139-141.
[86]
Ouyang, P.; Gottlieb, S.H.; Culotta, V.L.; Navas-Acien, A. EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes. Curr. Cardiol. Rep., 2015, 17(11), 96.
[87]
Wirebaugh, S.R.; Geraets, D.R. Apparent failure of edetic acid chelation therapy for the treatment of coronary atherosclerosis. Ann. Pharmacother., 1990, 24(1), 22-25.
[88]
Shrihari, J.S.; Roy, A.; Prabhakaran, D.; Reddy, K.S. Role of EDTA chelation therapy in cardiovascular diseases. Natl. Med. J. India, 2006, 19(1), 24-26.
[89]
Seely, D.M.; Wu, P.; Mills, E.J. EDTA chelation therapy for cardiovascular disease: A systematic review. BMC Cardiovasc. Disord., 2005, 5, 32.
[90]
Lamas, G.A.; Goertz, C.; Boineau, R.; Mark, D.B.; Rozema, T.; Nahin, R.L.; Lindblad, L.; Lewis, E.F.; Drisko, J.; Lee, K.L. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: The TACT randomized trial. JAMA, 2013, 309(12), 1241-1250.
[91]
Guldager, B.; Brixen, K.T.; Jorgensen, S.J.; Nielsen, H.K.; Mosekilde, L.; Jelnes, R. Effects of intravenous EDTA treatment on serum parathyroid hormone (1-84) and biochemical markers of bone turnover. Dan. Med. Bull., 1993, 40(5), 627-630.
[92]
Richardson, D.R.; Ponka, P. Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease. J. Lab. Clin. Med., 1998, 131(4), 306-315.
[93]
Richardson, D.R.; Baker, E. The release of iron and transferrin from the human melanoma cell. Biochim. Biophys. Acta, 1991, 1091(3), 294-302.
[94]
Richardson, D.R.; Hefter, G.T.; May, P.M.; Webb, J.; Baker, E. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II). Biol. Met., 1989, 2(3), 161-167.
[95]
Richardson, D.R. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process. Biochim. Biophys. Acta, 1997, 1320(1), 45-57.
[96]
Brittenham, G.M. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. Semin. Hematol., 1990, 27(2), 112-116.
[97]
Buss, J.L.; Ponka, P. Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs. Biochim. Biophys. Acta, 2003, 1619(2), 177-186.
[98]
Whitnall, M.; Suryo Rahmanto, Y.; Sutak, R.; Xu, X.; Becker, E.M.; Mikhael, M.R.; Ponka, P.; Richardson, D.R. The MCK mouse heart model of Friedreich’s ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc. Natl. Acad. Sci. USA, 2008, 105(28), 9757-9762.
[99]
Simunek, T.; Klimtova, I.; Kaplanova, J.; Sterba, M.; Mazurova, Y.; Adamcova, M.; Hrdina, R.; Gersl, V.; Ponka, P. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol. Res., 2005, 51(3), 223-231.
[100]
Buss, J.L.; Hermes-Lima, M.; Ponka, P. Pyridoxal isonicotinoyl hydrazone and its analogues. Adv. Exp. Med. Biol., 2002, 509, 205-229.
[101]
Simunek, T.; Boer, C.; Bouwman, R.A.; Vlasblom, R.; Versteilen, A.M.; Sterba, M.; Gersl, V.; Hrdina, R.; Ponka, P.; de Lange, J.J.; Paulus, W.J.; Musters, R.J. SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J. Mol. Cell. Cardiol., 2005, 39(2), 345-354.
[102]
Horackova, M.; Ponka, P.; Byczko, Z. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H(2)O(2) injury in adult cardiomyocytes. Cardiovasc. Res., 2000, 47(3), 529-536.
[103]
Simunek, T.; Sterba, M.; Popelova, O.; Kaiserova, H.; Adamcova, M.; Hroch, M.; Haskova, P.; Ponka, P.; Gersl, V. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. Br. J. Pharmacol., 2008, 155(1), 138-148.
[104]
Sterba, M.; Popelová, O.; Simůnek, T.; Mazurová, Y.; Potácová, A.; Adamcová, M.; Guncová, I.; Kaiserová, H.; Palicka, V.; Ponka, P.; Gersl, V. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: A study of salicylaldehyde isonicotinoyl hydrazone (SIH). Toxicology, 2007, 235(3), 150-166.
[105]
Sterba, M.; Popelova, O.; Simunek, T.; Mazurova, Y.; Potacova, A.; Adamcova, M.; Kaiserova, H.; Ponka, P.; Gersl, V. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. J. Pharmacol. Exp. Ther., 2006, 319(3), 1336-1347.
[106]
Kovarikova, P.; Klimes, J.; Sterba, M.; Popelova, O.; Mokry, M.; Gersl, V.; Ponka, P. Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study. J. Sep. Sci., 2005, 28(12), 1300-1306.
[107]
Hruskova, K.; Kovarikova, P.; Bendova, P.; Haskova, P.; Mackova, E.; Stariat, J.; Vavrova, A.; Vavrova, K.; Simunek, T. Synthesis and initial in vitro evaluations of novel antioxidant aroylhydrazone iron chelators with increased stability against plasma hydrolysis. Chem. Res. Toxicol., 2011, 24(3), 290-302.
[108]
Hruskova, K.; Potuckova, E.; Hergeselova, T.; Liptakova, L.; Haskova, P.; Mingas, P.; Kovarikova, P.; Simunek, T.; Vavrova, K. Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications. Eur. J. Med. Chem., 2016, 120, 97-110.
[109]
Richardson, D.R.; Bernhardt, P.V. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: An iron chelator with anti-tumour activity. J. Biol. Inorg. Chem., 1999, 4(3), 266-273.
[110]
Merlot, A.M.; Kalinowski, D.S.; Richardson, D.R. Novel chelators for cancer treatment: Where are we now? Antioxid. Redox Signal., 2013, 18(8), 973-1006.
[111]
Kalinowski, D.S.; Richardson, D.R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev., 2005, 57(4), 547-583.
[112]
Rao, V.A.; Zhang, J.; Klein, S.R.; Espandiari, P.; Knapton, A.; Dickey, J.S.; Herman, E.; Shacter, E.B. The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats. Cancer Chemother. Pharmacol., 2011, 68(5), 1125-1134.
[113]
Hasinoff, B.B.; Patel, D. The iron chelator Dp44mT does not protect myocytes against doxorubicin. J. Inorg. Biochem., 2009, 103(7), 1093-1101.
[114]
Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. USA, 2006, 103(40), 14901-14906.
[115]
Kovacevic, Z.; Chikhani, S.; Lovejoy, D.B.; Richardson, D.R. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: A new strategy for the treatment of pancreatic cancer. Mol. Pharmacol., 2011, 80(4), 598-609.
[116]
Lovejoy, D.B.; Sharp, D.M.; Seebacher, N.; Obeidy, P.; Prichard, T.; Stefani, C.; Basha, M.T.; Sharpe, P.C.; Jansson, P.J.; Kalinowski, D.S.; Bernhardt, P.V.; Richardson, D.R. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J. Med. Chem., 2012, 55(16), 7230-7244.
[117]
Sestak, V.; Stariat, J.; Cermanova, J.; Potuckova, E.; Chladek, J.; Roh, J.; Bures, J.; Jansova, H.; Prusa, P.; Sterba, M.; Micuda, S.; Simunek, T.; Kalinowski, D.S.; Richardson, D.R.; Kovarikova, P. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget, 2015, 6(40), 42411-42428.
[118]
Mladenka, P.; Macakova, K.; Filipsky, T.; Zatloukalova, L.; Jahodar, L.; Bovicelli, P.; Silvestri, I.P.; Hrdina, R.; Saso, L. In vitro analysis of iron chelating activity of flavonoids. J. Inorg. Biochem., 2011, 105(5), 693-701.
[119]
Mladenka, P.; Zatloukalova, L.; Filipsky, T.; Hrdina, R. Cardiovascular effects of flavonoids are not caused only by direct antioxidant activity. Free Radic. Biol. Med., 2010, 49(6), 963-975.
[120]
Randive, K.H.; Jaishree, V.; Patil, K.S.; Patil, K. Synthesis and biological evaluation of novel coumarin derivatives as antioxidant agents. Bioorg. Khim., 2015, 41(3), 366-374.
[121]
Mladenka, P.; Macakova, K.; Zatloukalova, L.; Rehakova, Z.; Singh, B.K.; Prasad, A.K.; Parmar, V.S.; Jahodar, L.; Hrdina, R.; Saso, L. In vitro interactions of coumarins with iron. Biochimie, 2010, 92(9), 1108-1114.
[122]
Kathuria, A.; Priya, N.; Chand, K.; Singh, P.; Gupta, A.; Jalal, S.; Gupta, S.; Raj, H.G.; Sharma, S.K. Substrate specificity of acetoxy derivatives of coumarins and quinolones towards Calreticulin mediated transacetylation: Investigations on antiplatelet function. Bioorg. Med. Chem., 2012, 20(4), 1624-1638.
[123]
Filipsky, T.; Riha, M.; Macakova, K.; Anzenbacherova, E.; Karlickova, J.; Mladenka, P. Antioxidant effects of coumarins include direct radical scavenging, metal chelation and inhibition of ROS-producing enzymes. Curr. Top. Med. Chem., 2015, 15(5), 415-431.
[124]
Najmanova, I.; Dosedel, M.; Hrdina, R.; Anzenbacher, P.; Filipsky, T.; Riha, M.; Mladenka, P. Cardiovascular effects of coumarins besides their antioxidant activity. Curr. Top. Med. Chem., 2015, 15(9), 830-849.
[125]
Lonnerdal, B.; Iyer, S. Lactoferrin: Molecular structure and biological function. Annu. Rev. Nutr., 1995, 15, 93-110.
[126]
Mladenka, P.; Semecky, V.; Bobrovova, Z.; Nachtigal, P.; Vavrova, J.; Holeckova, M.; Palicka, V.; Mazurova, Y.; Hrdina, R. The effects of lactoferrin in a rat model of catecholamine cardiotoxicity. Biometals, 2009, 22(2), 353-361.
[127]
Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J. Prodrugs: Design and clinical applications. Nat. Rev. Drug Discov., 2008, 7(3), 255-270.
[128]
Oliveri, V.; Vecchio, G. Prochelator strategies for site-selective activation of metal chelators. J. Inorg. Biochem., 2016, 162, 31-43.
[129]
Charkoudian, L.K.; Pham, D.M.; Kwon, A.M.; Vangeloff, A.D.; Franz, K.J. Modifications of boronic ester pro-chelators triggered by hydrogen peroxide tune reactivity to inhibit metal-promoted oxidative stress. Dalton Trans., 2007, 43, 5031-5042.
[130]
Kielar, F.; Helsel, M.E.; Wang, Q.; Franz, K.J. Prochelator BHAPI protects cells against paraquat-induced damage by ROS-triggered iron chelation. Metallomics, 2012, 4(9), 899-909.
[131]
Charkoudian, L.K.; Dentchev, T.; Lukinova, N.; Wolkow, N.; Dunaief, J.L.; Franz, K.J. Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide. J. Inorg. Biochem., 2008, 102(12), 2130-2135.
[132]
Simon, J.; Salzbrunn, S.; Prakash, G.K.; Petasis, N.A.; Olah, G.A. Regioselective conversion of arylboronic acids to phenols and subsequent coupling to symmetrical diaryl ethers. J. Org. Chem., 2001, 66(2), 633-634.
[133]
Jansova, H.; Bures, J.; Machacek, M.; Haskova, P.; Jirkovska, A.; Roh, J.; Wang, Q.; Franz, K.J.; Kovarikova, P.; Simunek, T. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. Toxicology, 2016, 350-352, 15-24.
[134]
Bureš, J.; Jansová, H.; Stariat, J.; Filipský, T.; Mladěnka, P.; Šimůnek, T.; Kučera, R.; Klimeš, J.; Wang, Q.; Franz, K.J.; Kovaříková, P. LC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH). J. Pharm. Biomed. Anal., 2015, 105, 55-63.
[135]
Charkoudian, L.K.; Pham, D.M.; Franz, K.J. A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. J. Am. Chem. Soc., 2006, 128(38), 12424-12425.
[136]
Swain, S.M.; Vici, P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J. Cancer Res. Clin. Oncol., 2004, 130(1), 1-7.
[137]
Hasinoff, B.B. The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions, 1989, 26(3-4), 378-385.
[138]
Deng, S.; Yan, T.; Jendrny, C.; Nemecek, A.; Vincetic, M.; Godtel-Armbrust, U.; Wojnowski, L. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC Cancer, 2014, 14, 842.
[139]
Lyu, Y.L.; Kerrigan, J.E.; Lin, C.P.; Azarova, A.M.; Tsai, Y.C.; Ban, Y.; Liu, L.F. Topoisomerase IIbeta mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res., 2007, 67(18), 8839-8846.
[140]
Vavrova, A.; Jansova, H.; Mackova, E.; Machacek, M.; Haskova, P.; Tichotova, L.; Sterba, M.; Simunek, T. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. PLoS One, 2013, 8(10), e76676.
[141]
Lencova-Popelova, O.; Jirkovsky, E.; Jansova, H.; Jirkovska-Vavrova, A.; Vostatkova-Tichotova, L.; Mazurova, Y.; Adamcova, M.; Chladek, J.; Hroch, M.; Pokorna, Z.; Gersl, V.; Simunek, T.; Sterba, M. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane. J. Mol. Cell. Cardiol., 2016, 91, 92-103.
[142]
Hasinoff, B.B. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovasc. Toxicol., 2002, 2(2), 111-118.
[143]
Zatloukalova, L.; Filipsky, T.; Mladenka, P.; Semecky, V.; Macakova, K.; Holeckova, M.; Vavrova, J.; Palicka, V.; Hrdina, R. Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity. Can. J. Physiol. Pharmacol., 2012, 90(4), 473-484.
Download PDF Flyer